cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Io Biotech Inc
5 own
3 watching
Current Price
$1.44
$-0.04
(-2.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
87.29M
52-Week High
52-Week High
2.64000
52-Week Low
52-Week Low
0.81600
Average Volume
Average Volume
0.08M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization87.29M
icon52-Week High2.64000
icon52-Week Low0.81600
iconAverage Volume0.08M
iconDividend Yield--
iconP/E Ratio--
What does the Io Biotech Inc do?
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company s lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Read More
How much money does Io Biotech Inc make?
News & Events about Io Biotech Inc.
Globe Newswire
1 year ago
Mr. Smith joins IO Biotech bringing over two decades of legal and compliance experience in the life science industriesNEW YORK, Jan. 23, 2023 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-...
Globe Newswire
1 year ago
Independent data monitoring committee recommends that the companys Phase 3 trial evaluating IO102-IO103 in combination with pembrolizumab in first-line advanced melanoma patients continue without any modifications; the trial is enrolling patients at more than 80 active sites globally. Encouraging ...
Benzinga
1 year ago
Latest Ratings for IOBT DateFirmActionFromTo Nov 2021Morgan StanleyInitiates Coverage OnOverweight Nov 2021Cowen & Co.Initiates Coverage OnOutperform Nov 2021JefferiesInitiates Coverage OnBuy View More Analyst Ratings for IOBT View the Latest Analyst Ratings read more...
Globe Newswire
1 year ago
NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, announced today that Mai-Britt Zocca, Ph.D., the companys President and CEO, and Amy Sullivan...
Globe Newswire
1 year ago
NEW YORK, Oct. 05, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win technology platform, announced an oral presentation and two poster presentations at the Society for Immunotherapy ...
Frequently Asked Questions
Frequently Asked Questions
What is Io Biotech Inc share price today?
plus_minus_icon
Can Indians buy Io Biotech Inc shares?
plus_minus_icon
How can I buy Io Biotech Inc shares from India?
plus_minus_icon
Can Fractional shares of Io Biotech Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Io Biotech Inc stocks?
plus_minus_icon
What is today’s traded volume of Io Biotech Inc?
plus_minus_icon
What is today’s market capitalisation of Io Biotech Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Io Biotech Inc?
plus_minus_icon
What percentage is Io Biotech Inc down from its 52-Week High?
plus_minus_icon
What percentage is Io Biotech Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$1.44
$-0.04
(-2.7%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00